cp 115953 has been researched along with etoposide in 11 studies
| Studies (cp 115953) | Trials (cp 115953) | Recent Studies (post-2010) (cp 115953) | Studies (etoposide) | Trials (etoposide) | Recent Studies (post-2010) (etoposide) |
|---|---|---|---|---|---|
| 20 | 0 | 0 | 18,306 | 3,693 | 4,900 |
| Protein | Taxonomy | cp 115953 (IC50) | etoposide (IC50) |
|---|---|---|---|
| nuclear receptor coactivator 1 isoform 1 [Homo sapiens] | Homo sapiens (human) | 1.153 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 1.4284 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 3.187 | |
| Caspase-3 | Homo sapiens (human) | 1 | |
| DNA topoisomerase 2-beta | Homo sapiens (human) | 0.4299 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (90.91) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aldous, SC; Coughlin, SA; Dorff, PH; Gruett, MD; Lesher, GY; Rake, JB; Reuman, M; Singh, B; Wentland, MP | 1 |
| Gootz, TD; Martin, BA; McGuirk, PR; Moynihan, M; Osheroff, N; Robinson, MJ; Sutcliffe, JA | 1 |
| Chung, IK; Gootz, TD; McGuirk, PR; Muller, MT; Spitzner, JR | 1 |
| Elsea, SH; Hsiung, Y; Nitiss, JL; Osheroff, N | 1 |
| Forsgren, A; Riesbeck, K | 1 |
| Corbett, AH; Elsea, SH; Osheroff, N; Westergaard, M | 1 |
| Corbett, AH; Osheroff, N; Robinson, MJ | 1 |
| Corbett, AH; Hong, D; Osheroff, N | 1 |
| Burden, DA; Elsea, SH; Lomenick, JP; Osheroff, N; Westergaard, M | 1 |
| Anderson, VE; Gootz, TD; Kaczmarek, FS; Osheroff, N; Zaniewski, RP | 1 |
| Bromberg, KD; Burgin, AB; Osheroff, N | 1 |
1 review(s) available for cp 115953 and etoposide
| Article | Year |
|---|---|
Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.
Topics: Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; DNA; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Fluoroquinolones; Genistein; Humans; Isoflavones; Models, Structural; Quinolones; Topoisomerase II Inhibitors | 1994 |
10 other study(ies) available for cp 115953 and etoposide
| Article | Year |
|---|---|
Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives.
Topics: Animals; Anti-Infective Agents; Fluoroquinolones; HeLa Cells; Humans; Leukemia P388; Mice; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1993 |
Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
Topics: Animals; Anti-Infective Agents; Catalysis; Cell Line; Cell Survival; Cricetinae; Cricetulus; DNA; DNA Topoisomerases, Type II; Drosophila melanogaster; Electrophoresis, Agar Gel; Etoposide; Fluoroquinolones; Hydrolysis; Molecular Structure; Quinolones | 1991 |
Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Topics: Amsacrine; Anti-Infective Agents; Base Sequence; DNA; DNA Topoisomerases, Type II; Etoposide; Fluoroquinolones; Humans; Hydrolysis; Molecular Sequence Data; Quinolones; Teniposide; Topoisomerase II Inhibitors | 1995 |
A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
Topics: Anti-Infective Agents; Base Sequence; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Escherichia coli; Etoposide; Fluoroquinolones; Genes, Bacterial; Genes, Fungal; Kinetics; Macromolecular Substances; Molecular Sequence Data; Mutagenesis, Site-Directed; Oligodeoxyribonucleotides; Point Mutation; Quinolones; Recombinant Proteins; Saccharomyces cerevisiae; Serine; Species Specificity; Tryptophan | 1995 |
CP-115,953 stimulates cytokine production by lymphocytes.
Topics: Anti-Infective Agents; Cells, Cultured; Cytokines; DNA Damage; Etoposide; Fluoroquinolones; Humans; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Novobiocin; Quinolones; RNA, Messenger; T-Lymphocytes; Thymidine; Topoisomerase II Inhibitors | 1995 |
Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Topics: Adenosine Triphosphate; Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; Cell Nucleus; DNA Topoisomerases, Type II; DNA, Bacterial; Drosophila melanogaster; Escherichia coli; Etoposide; Fluoroquinolones; Genistein; Hydrolysis; Isoflavones; Novobiocin; Plasmids; Quercetin; Quinolones; Topoisomerase II Inhibitors | 1993 |
Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Topics: Amsacrine; Animals; Anti-Infective Agents; Binding Sites; Cell Line; Cell Nucleus; DNA; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Drug Interactions; Etoposide; Fluoroquinolones; Genistein; Growth Inhibitors; Isoflavones; Kinetics; Novobiocin; Protein Binding; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1993 |
Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Topics: Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; CHO Cells; Ciprofloxacin; Cricetinae; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Electrophoresis, Agar Gel; Enzyme Activation; Etoposide; Fluoroquinolones; Genistein; Isoflavones; Kinetics; Molecular Structure; Quinolones | 1997 |
Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
Topics: Anti-Infective Agents; Biological Evolution; Ciprofloxacin; DNA Damage; DNA Repair; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Escherichia coli; Etoposide; Fluoroquinolones; Gram-Positive Bacteria; Kinetics; Quinolones; Staphylococcus aureus | 1999 |
Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
Topics: Amino Acid Substitution; Anti-Infective Agents; Antigens, Neoplasm; Antineoplastic Agents; Base Sequence; Binding Sites; Catalytic Domain; DNA; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Activation; Etoposide; Fluoroquinolones; Humans; In Vitro Techniques; Kinetics; Models, Biological; Oligodeoxyribonucleotides; Recombinant Proteins; Substrate Specificity | 2003 |